期刊文献+

强化健康教育在非酒精性脂肪性肝病治疗中的作用 被引量:3

The role of enhanced health education in the management of nonalcoholic fatty liver disease
下载PDF
导出
摘要 目的研究强化健康教育在非酒精性脂肪性肝病(NAFLD)治疗中的作用。方法将62例NAFLD患者随机分为强化健康教育组和对照组。两组都给予生活方式指导,血清转氨酶升高者给予保肝药物及对症等治疗。强化健康教育组在上述治疗的基础上,每2周左右通过手机短信或电话等方式对强化健康教育组患者进行督促和鼓励,强调改变生活方式的重要性,指导合理的饮食和运动习惯。6个月后,复查患者的体质量、腰围、肝功能试验、血糖、血脂、腹部超声等。结果 6个月后,2组患者的体质量、腰围、肝功能试验、血糖、血脂、腹部超声等都有不同程度的好转,强化健康教育组患者的疗效更为显著。结论 NAFLD的发病与患者的生活方式密切相关,对患者进行生活方式指导的强化健康教育有利于患者的恢复。 Objective To study the role of enhanced health education in the management of nonalcoholic fatty liver disease(NAFLD).Methods Sixty-two patients with NAFLD were randomized into enhanced health education group and control group.Essential life-style guidance was given to all patients,and hepatocyte protective agents and symptomatic treatment were added to patients with elevated amino transferase levels.Besides above measures,patients in enhanced health education group were urged and encouraged additionally by call and/or information through mobile telephones every 2 weeks,emphasizing the importance of life-style modification and instructing the healthy habits of diets and exercises.After 6 months,the patients in both groups were re-examined for the items including body mass,waist circumference,liver function tests,blood glucose and lipids as well as abdominal sonography.Results After 6 months,all the items including body mass,waist circumference,liver function tests,blood glucose and lipids as well as abdominal sonography were improved in both groups.However,the efficacy was more significant in enhanced health education group compared with control group.Conclusion The pathogenesis of NAFLD was closely related to unhealthy life-style of the patients.Guidance of healthy life-style by enhanced health education was efficient for the patients' recovery.
出处 《临床和实验医学杂志》 2011年第3期174-175,178,共3页 Journal of Clinical and Experimental Medicine
关键词 非酒精性脂肪性肝病 健康教育 治疗 Nonalcoholic fatty liver disease Health education Treatment
  • 相关文献

参考文献6

  • 1Fan JG,Farrell GC.Epidemiology of non alcoholic fatty liver disease in China[J].J Hepatol,2009,50(1):204-210.
  • 2Sderberg C,Stl P,Askling J,et al.Decreased survival of subjects with elevated liver function tests during a 28-year follow-up[J].Hepatology,2010,51(2):595-602.
  • 3非酒精性脂肪性肝病诊疗指南[J].肝脏,2006,11(1):68-70. 被引量:190
  • 4范建高.非酒精性脂肪性肝病诊疗指南(2010年修订版)[J].胃肠病学和肝病学杂志,2010,19(6):483-487. 被引量:409
  • 5Promrat K,Kleiner DE,Niemeier HM,et al.Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis[J].Hepatology,2010,51:121-129.
  • 6Chavez-Tapia NC,Tellez-Avila FI,Barrientos-Gutierrez T,et al.Bariatric surgery for non-alcoholic steatohepatitis in obese patients[J].Cochrane Database Syst Rev,2010,(1):CD007340.

二级参考文献22

  • 1Fan, Jian-Gao,Peng, Yong-De.Metabolic syndrome and non-alcoholic fatty liver disease:Asian definitions and Asian studies[J].Hepatobiliary & Pancreatic Diseases International,2007,6(6):572-578. 被引量:42
  • 2范建高.糖尿病与肝病的关系及其诊治对策[J].中华糖尿病杂志,2009,1(4). 被引量:30
  • 3胡国平,刘凯,赵连三.多烯磷脂酰胆碱(易善复)治疗酒精性肝病和脂肪肝的系统评价[J].肝脏,2005,10(1):5-7. 被引量:108
  • 4Lok AS,McMahon BJ; Practice Guidelines Committee,American Association for the Study of Liver Diseases (AASLD).Chronic hepatitis B:update of recommendations.Hepatology,2004,39:857-861.
  • 5Farrell GC,George J,Pauline de la M.Hall and McCullough A J,eds.Fatty liver disease:NASH and related disorders.Oxford:Blackwell Publishing,2005,1-22.
  • 6American Gastroenterological Association.American Gastroenterological Association Medical Position Statement:nonalcoholic fatty liver disease.Gastroenterology,2002,123:1702-1704.
  • 7Sanyal AJ.AGA technical review on nonalcoholic fatty liver disease.Gastroenterology,2002,123:1705-1725.
  • 8Ramesh S,Sanyal AJ.Evaluation and management of non-alcoholic steatohepatitis.J Hepatol,2005,42:S2-S12.
  • 9Eckel RH,Grundy SM,Zimmet PZ.The metabolic syndrome.Lancet,2005,365:1415-1428.
  • 10Graif M,Yanuka M,Baraz M,et al.Quantitative estimation of attenuation in ultrasound video images:correlation with histology in diffuse liver disease.Invest Radiol,2000,35:319-324.

共引文献596

同被引文献30

  • 1Rotman Y,Koh C,Zmuda JM,et al.The association of genetic variability in patatin-like phospholipase do-main-containing protein3(PNPLA3)with histological severity of nonalcoholic fatty liver disease[J].Hepatolo-gy,2010,52(3):894.
  • 2Promrat K,Kleiner DE,Niemeier HM,et al.Randomized controlled trial testing the effects of weight loss on nonal-coholic steatohepatitis[J].Hepatology,2010,51(1):121.
  • 3Lazo M,Solga SF,Horska A,et al.Effect of a12-month intensive lifestyle intervention on hepatic steatosis in adults with type2diabetes[J].Diabetes Care,2010,33(10):2156.
  • 4Fujita N,Takei Y.Iron overload in nonalcoholic steatohep-atitis[J].Adv Clin Chem,2011,55:105.
  • 5Hussein O,Grosovski M,Schlesinger S,et al.Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis(NASH)[J].Dig Dis Sci,2007,52(10):2512.
  • 6Harrison SA,Fecht W,Brunt EM,et al.Orlistat for over-weight subjects with nonalcoholic steatohepatitis:a ran-domized,prospective trial[J].Hepatology,2009,49(1):80.
  • 7Kenny PR,Brady DE,Torres DM,et al.Exenatide in the treatment of diabetic patients with non-alcoholic steato-hepatitis:a case series[J].Am J Gastroenterol,2010,105(12):2707.
  • 8Sharma S,Mells JE,Fu PP,et al.GLP-1analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroau-tophagy[J].Plos One,2011,6(9):e25269.
  • 9Balaban YH,Korkusuz P,Simsek H,et al.Dipeptidyl peptidaseⅣ(DDPⅣ)in NASH patients[J].Ann Hepa-tol,2007,6(4):242.
  • 10Yilmaz Y,Atug O,Yonal O,et al.Dipeptidyl peptidaseⅣinhibitors:therapeutic potential in nonalcoholic fatty liver disease[J].Med Sci Monit,2009,15(4):HY1.

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部